“…Among malignancies, CD30-positive T-cells typically characterize lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (cALCL) [ 1 , 36 ], whereas in B-cell neoplasms CD30-positive cells are less common, occurring in the setting of iatrogenic immunosuppression (i.e., mucocutaneous ulcers) [ 1 , 37 ], and in primary cutaneous diffuse large B-cell lymphomas (DLBCL) [ 38 ]. CD30 expression has also been reported in a variable number of neoplastic cells of primary cutaneous follicle center lymphoma (PCFCL) and of primary cutaneous marginal zone lymphoma (PCMZL) [ 14 , 15 , 39 , 40 , 41 , 42 ], with rare cases describing a Hodgkin and Reed–Sternberg (H/RS)-like morphology [ 26 , 43 , 44 ].…”